MX2014010958A - Composicion de celulas inmunoestimuladora activada y sus usos. - Google Patents

Composicion de celulas inmunoestimuladora activada y sus usos.

Info

Publication number
MX2014010958A
MX2014010958A MX2014010958A MX2014010958A MX2014010958A MX 2014010958 A MX2014010958 A MX 2014010958A MX 2014010958 A MX2014010958 A MX 2014010958A MX 2014010958 A MX2014010958 A MX 2014010958A MX 2014010958 A MX2014010958 A MX 2014010958A
Authority
MX
Mexico
Prior art keywords
immunostimulatory cell
cell composition
activated immunostimulatory
activated
methods
Prior art date
Application number
MX2014010958A
Other languages
English (en)
Spanish (es)
Inventor
Irene Ginis
Alan Smith
Marina Bubis
Mitchell Shirvan
Adi Zuloff-Shani
Original Assignee
Macrocure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrocure Ltd filed Critical Macrocure Ltd
Publication of MX2014010958A publication Critical patent/MX2014010958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2014010958A 2012-03-15 2013-03-13 Composicion de celulas inmunoestimuladora activada y sus usos. MX2014010958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611202P 2012-03-15 2012-03-15
PCT/IB2013/000848 WO2013136182A1 (en) 2012-03-15 2013-03-13 Activated immunostimulatory cell composition and uses thereof

Publications (1)

Publication Number Publication Date
MX2014010958A true MX2014010958A (es) 2015-11-18

Family

ID=48326349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010958A MX2014010958A (es) 2012-03-15 2013-03-13 Composicion de celulas inmunoestimuladora activada y sus usos.

Country Status (8)

Country Link
US (1) US20150030635A1 (enExample)
EP (1) EP2825634A1 (enExample)
JP (1) JP2015516374A (enExample)
CA (1) CA2865553A1 (enExample)
IN (1) IN2014DN08093A (enExample)
MX (1) MX2014010958A (enExample)
RU (1) RU2014140792A (enExample)
WO (1) WO2013136182A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2613765A2 (en) 2010-09-09 2013-07-17 Macrocure, Ltd. Activated leukocyte conditioned supernatant and uses for wound healing
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
EP3344286B1 (en) * 2015-09-02 2021-03-10 The Cleveland Clinic Foundation Ovarian cancer vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7935531B2 (en) 2000-02-22 2011-05-03 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
EP1810691A3 (en) * 2001-10-26 2008-03-26 IRX Therapeutics, Inc. Immunotherapy for reversing immune suppression
EP1569514A4 (en) 2002-08-16 2007-10-31 SPECIFIC ANTIGEN OF TUMORS, PEPTIDES ASSOCIATED THERETO AND USE THEREOF AS IMMUNOMINAL VACCINES
US8012468B2 (en) 2004-06-11 2011-09-06 Catholic Universtiy Industry Academic Cooperation Foundation Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
CA2642994C (en) 2006-02-24 2015-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic page-4 peptides and methods of use
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
WO2008127285A2 (en) 2006-10-05 2008-10-23 The Board Of Trustees Of The University Of Arkansas Target peptides for ovarian cancer immunotherapy
WO2010100570A2 (en) 2009-03-05 2010-09-10 Macrocure, Ltd. Activated leukocyte composition
EP2613765A2 (en) * 2010-09-09 2013-07-17 Macrocure, Ltd. Activated leukocyte conditioned supernatant and uses for wound healing

Also Published As

Publication number Publication date
CA2865553A1 (en) 2013-09-19
EP2825634A1 (en) 2015-01-21
IN2014DN08093A (enExample) 2015-05-01
RU2014140792A (ru) 2016-05-10
WO2013136182A1 (en) 2013-09-19
US20150030635A1 (en) 2015-01-29
JP2015516374A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
EA201490381A1 (ru) Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl)
PL3313991T3 (pl) Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
UY34456A (es) Anticuerpos anti-il-36r
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
MX2016007063A (es) Peptidos terapeuticos.
MX373334B (es) Composiciones y métodos.
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX2015015231A (es) Métodos y composiciones para mejorar las células t reguladoras de cd4+.
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
AR090923A1 (es) Anticuerpos anti-il-23
EA201290884A1 (ru) Устойчивые к спирту кишечнорастворимые фармацевтические композиции
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
IN2014DN06104A (enExample)
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
BR112015012907A2 (pt) composição de cuidado pessoal
MX359769B (es) Metodos para descelularizar huesos.
UY34751A (es) ?composición de pienso para reducir la metanogénesis en rumiantes?
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
MX2015003701A (es) Composiciones para tratamiento.
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer